“…Support for such applications comes from the previous identification of an endogenous 43 kD papain inhibitor from psoriatic scale. 44,45 This 43 kD papain inhibitor has subsequently been demonstrated in lesions of ichthyosis, eczema, actinic keratosis, verruca, condyloma, molluscum, Bowen's disease, and squamous cell carcinoma, as well as in fetal skin. 46,47 This is further underscored by a recent study that demonstrated defects in endogenous SCCE expression in squamoproliferative disorders such as actinic keratosis, ichthyosis vulgaris, and squamous cell carcinoma in situ.…”